Nyxoah SA

NYXH
About the company

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Country: BelgiumPrice: $0.90Market Cap: $91.6M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #3022 (Top 97.6%)FAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 6✗ 22▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.7x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-116.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-116.7%, ROC=-989.5%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.7x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-89.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.7x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low105% of trailing low ($0.86)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-115.52%; #5460/6340 (top 86.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.6300; #2425/6449 (top 37.6%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-79.5%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.1285; #4181/5247 (top 79.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-89.49%; #4036/4519 (top 89.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-69.49%; #5645/6202 (top 91.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-82.0M
      ✗LynchPositive and growing
      Operating Cash Flow$-81.0M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-58.22%, ROA=-76.04%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-89.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-211.7%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/7 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-82.0M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-89.49%; #4036/4519 (top 89.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 3✗ 10▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 11.5% vs Rev: 150.2%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.83 (2020) -> $-2.78 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth43.5%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency1/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 61.9% -> 63.1%, operating margin -1037.3% -> -833.2%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR168.2%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio1.25
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-76.9%
      ✗Buffett> 10%
      ROIC - WACC-86.9%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-989.5%
      ✗Greenblatt> 25%
      Current Ratio Change YoY4.56 -> 1.25
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.03x -> 0.08x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities1.25
      ✗Dreman> 1.5
      Return on Invested Capital-130.5%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-34.9%; FY2024: ROIC=-39.7%; FY2025: ROIC=-130.5%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -130.5%)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 15▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #3022✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #2307/2370 (Top 97.3%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag NYXH's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/7 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/7 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-64.9%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-833.2% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-183.4%
      ✗Lynch> 15%
      EBIT / Enterprise Value-116.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-116.7%, ROC=-989.5%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-76.04%
      ✗PiotroskiROA > 0
      ROA Change YoY-37.40% -> -76.04% (delta: -38.64%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-58.22%, ROA=-76.04%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY65.7% -> 63.1%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-889.0%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-183.4%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.7x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-93.3% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-833.2%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-183.4%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-1037.3% (2023) -> -833.2% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 61.9% -> 63.1%, operating margin -1037.3% -> -833.2%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-115.52%; #5460/6340 (top 86.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+5.34%; #3085/3702 (top 83.3%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-183.36%; #4846/5226 (top 92.7%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.2101; #4280/5884 (top 72.7%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/6 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage50% pass✓ 9✗ 6▾

      6 of 12 pass — Graham, Buffett, Lynch +3 more object

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.03, IC: -7.2x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.03
      ✓Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.25
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.03
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.03
      ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-7.2x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.03
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.0288; #835/4210 (top 19.8%)
      ✓AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($91.6M)
    Revenue: $11.8M+150.2% YoY
    Net Income: $105.8M-71.7% YoY

    Financial Snapshot

    Operating Margin-833.2%
    Return on Equity-183.4%
    Debt / Equity0.03
    Current Ratio1.25
    EPS (Diluted)$-2.78
    Shares Retired−15.0% / −50.1% 2y

    Shareholder Return

    Fiscal 2025

    Issued 15.0% of shares last year, 50.1% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    MetricFY 2025
    Sources
    • 20-F · 2026-03-26
    FY 2024
    Sources
    • 20-F · 2025-03-20
    FY 2023
    Sources
    • 20-F · 2024-03-20
    FY 2022
    Sources
    • 20-F · 2023-03-22
    FY 2021
    Sources
    • 20-F · 2023-03-22
    Market Cap$91.6Mcurrent$404.2Mest.$310.3Mest.$139.3Mest.$510.8Mest.
    Revenue$11.8M↑150%$4.7M$4.7M↑44%$3.3M↑241%$964.9K
    Operating Income-$98.1M↓60%-$61.2M↓25%-$48.9M↓41%-$34.6M↓17%-$29.7M
    Net Income-$105.8M↓72%-$61.6M↓31%-$46.9M↓41%-$33.3M↓6%-$31.3M
    EPS (Diluted)$-2.78↓48%$-1.88↓12%$-1.68↓30%$-1.29↑2%$-1.31
    Gross Margin63.1%↓4%65.7%↑6%61.9%↓1%62.7%↓3%64.4%
    Operating Margin-833.2%↑36%-1300.8%↓25%-1037.3%↑2%-1053.8%↑66%-3080.0%
    ROE-183.4%↓251%-52.3%↓19%-44.1%↓70%-26.0%↓40%-18.6%
    Total Debt$1.7M↓57%$3.8M↓11%$4.3M↑22%$3.5M↓13%$4.1M
    Shareholders' Equity$57.7M↓51%$117.9M↑11%$106.4M↓17%$128.3M↓24%$168.3M
    Current Ratio1.25↓73%4.56↓4%4.73↓30%6.72↓44%12.10
    Debt / Equity0.03↓11%0.03↓20%0.04↑47%0.03↑14%0.02
    Operating Cash Flow-$81.0M↓58%-$51.2M↓5%-$48.6M↓59%-$30.7M↓7%-$28.7M
    Free Cash Flow-$82.0M↓56%-$52.4M↓2%-$51.3M↓62%-$31.6M↓4%-$30.4M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    NYXH vs Peers — Financial Grading

    Revenue$11.8MBottom 25%
    Net Income$105.8MBottom 25%
    ROE-183.4%Bottom 25%
    D/E0.03Top 25%
    Op. Margin-833.2%Bottom 25%
    Curr. Ratio1.25Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11